Instrument Inactif

Communiqués Durata Therapeutics Inc

Actions

US26658A1079

Recherche biotechnologique et médicale

Cours en clôture Nasdaq
- ^USD	-

06/10/14	Salix Pharmaceuticals : USA/Pharmacie-Actavis acquiert Durata pour $675 millions	RE
06/10/14	Actavis : USA/Pharmacie-Activis acquiert Durata pour $675 millions	RE

Communiqués

01/06/15	Durata Therapeutics : Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults	PU
27/05/15	Durata Therapeutics : Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections	PU
08/04/15	Durata Therapeutics : Actavis Confirms Generic Letairis® Patent Challenge	PU
03/04/15	Durata Therapeutics : Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors	PU
12/03/15	Durata Therapeutics : Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan	PU
09/03/15	Durata Therapeutics : Actavis Confirms District Court Ruling In Atelvia® Patent Litigation	PU
04/03/15	Durata Therapeutics : Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan	PU
04/03/15	Durata Therapeutics : Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)	PU
02/03/15	Durata Therapeutics : Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years	PU
02/03/15	Durata Therapeutics : Actavis Receives U.S. FDA Approval for AVYCAZ™ (CEFTAZIDIME-AVIBACTAM)	PU
27/02/15	Durata Therapeutics : Actavis Confirms Generic Uceris® Patent Challenge	PU
25/02/15	Durata Therapeutics : Actavis Receives Final Approval for Generic Version of Subutex®	PU
18/02/15	Durata Therapeutics : Actavis to Divest Doryx® to Mayne Pharma	PU
17/02/15	Durata Therapeutics : Actavis Launches Generic Pulmicort RESPULES®	PU
09/02/15	Durata Therapeutics : Actavis to Divest Rights to Branded Respiratory Portfolio in the U.S. and Canada to AstraZeneca	PU
26/01/15	Durata Therapeutics : Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia	PU
20/01/15	Durata Therapeutics : Actavis Launches U.S. Generic Specialty Injectable Portfolio	PU
13/01/15	Durata Therapeutics : Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings	PU
13/01/15	Durata Therapeutics : Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR	PU
06/01/15	Durata Therapeutics : Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension	PU
24/12/14	Durata Therapeutics : Actavis Names Jonathon Kellerman Executive Vice President, Global Chief Compliance Officer	PU
24/12/14	Durata Therapeutics : Actavis to Present at 33rd Annual J.P. Morgan Healthcare Conference	PU
23/12/14	Durata Therapeutics : XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Adults	PU
23/12/14	Durata Therapeutics : Actavis to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference	PU
16/12/14	Durata Therapeutics : Actavis Will Appeal Injunction Requiring Continued Distribution of NAMENDA® IR	PU